Category: Baystreet Newswire
Company: TDM Financial
RNA interference ("RNAi") therapeutics may have experienced some hurdles in the past, but favorable clinical results have boosted their profile in recent months. With new data supporting both safety and efficacy, larger pharmaceutical companies are starting to regain confidence in the sector. These dynamics have sparked a number of new deals and collaborations that have boosted industry valuations and opened the door to new opportunities.
RNAi therapeutics aim to silence the production of proteins that are associated with certain diseases and conditions. For example,
In this article, we'll take a look at some of the recent deals in the RNAi space and explore where the best opportunities remain.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Genzyme, a
The move came shortly after Alnylam acquired Merck & Co., Inc.'s (NYSE: MRK) subsidiary
Alnylam's alliance with Sanofi demonstrates Big Pharma's renewed confidence in RNAi therapeutics particularly given the deal's wide scope and equity component. Shares in Alnylam jumped more than 30% on the day of the news and trades up 40.9% over the past month despite the fact that the deal involved the issuance of
Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Biogen Idec Inc. (NASDAQ: BIIB) signed a deal last September to develop drugs targeting neurological disorders. Under the six-year deal, Biogen will pay Isis
The news also comes nine months after Isis obtained
Isis' expanded deal with Biogen represents increasing confidence in RNA-based therapeutics like oligonucleotides, on the part of Big Pharma. Since
RXi Could Sign the Next Deal
While RXI-109's results have been positive, the company's real potential lies in licensing its sd-rxRNA platform to larger pharmaceutical companies through collaborations similar to Alnylam's alliance with Sanofi or Isis' deal with Biogen. The self-delivering RNAi platform has demonstrated spontaneous cellular uptake and a significant, sustained and reproducible silencing of the targeted mRNA in a market where delivery is exceedingly important.
Learn More about RXi Pharmaceuticals Here:http://www.emerginggrowthcorp.com/emailassets/rxii/rxii_landing.php
Investing in RNAi's Growth
The RNAi industry has finally turned a corner with favorable data,
For more information about
Company Website http://www.rxipharma.com/Recent SEC Filings http://secfilings.com/SearchResults.aspx?name=Rxi%20Pharmaceuticals%20Corp
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- U.S. Consumer Sentiment Falls in Early March
- Vybz Kartel Convicted of Murder
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- Keurig Adds Peet's coffee, Alters Starbucks deal
- Quiznos Files for Chapter 11
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Koch Brothers Step up Anti-Obamacare Campaign
- U.S. to Relinquish Gov't Control Over Internet
- Is Malaysian Airlines Flight 370 in Andaman Sea?